]>
IRCT20180204038608N1 IRCT 2018-03-21 Tabriz University of Medical Sciences Effect of Fingolimod in Multiple Sclerosis Comparison of Fingolimod whit Interferon Therapy in Patients with Multiple Sclerosis 2018-03-21 anticipated 30 Complete https://irct.ir/trial/29466 interventional Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment. 2 Multiple Sclerosis. Intervention group:capsule Fingolimod 0.5 mg daily for one year. Yes - There is a plan to make this available What will be shared: main outcome report When: Available from 1399 To whom: Academic researchers Conditions: Using of this study in other researches is admissible. Where to obtain: Tabriz University of Medical Sciences site , www.Tbzmed.ac.ir ,centlibrary.tbzmed.ac.ir How to obtain: In order to get this document, one can refer to the university website ,or he /she can refer to the library of Tabriz university of medical sciences. Comments:
public Sheida Shaafi
No 3,Floor 1,Elgoli st ,Razi hospital,Tabriz ,Iran
Tabriz Iran (Islamic Republic of) 5166614766 +98 41 3380 4486 info@prazi.tbzmed.ac.ir Tabriz University of Medical Sciences scientific Sheida Shaafi
No 3,Floor 1,Elgoli st,Razi hospital,Tabriz,Iran
Tabriz Iran (Islamic Republic of) 5166614766 +98 41 3381 0810 Shaafis@tbzmed.ac.ir Tabriz University of Medical Sciences Iran (Islamic Republic of) Age should be between 18 to 55 years old The type of disease should be Relapsing Remitting There should not be any evidence of relapse in the past 30 days EDSS score should be between 0 to 5.5 18 years 55 years Both Have Relapse or use of Corticosteroids in the past 30 days Have an active infection Have a history of diabetes Have cardiac problems and use of anti arrhythmic drugs Taking drugs such as Azathioprine and Methotrexate WBCs less than 3500 and lymphocyte count less than 800 Taking heart beat reducer drugs G35 Multiple sclerosis Treatment - Drugs Intervention group:capsule Fingolimod 0.5 mg daily for one year Disease disability score,Annualized Relapse rate. Timepoint: Determining of Disease disability score at the beginning of study and after one year,Relapse rate during the past year and one year after starting Fingolimod. Method of measurement: Expanded Disability Status Scale score ,Annualized Relapse rate with negative bi nominal regression. Tabriz University of Medical Sciences Approved 2016-07-25 Ethics committee of Tabriz University of Medical Sciences No.2,centeral building,university of Medical Sciences,Golgasht ave,Tabriz Tabriz East Azarbaijan Iran (Islamic Republic of)